Live Breaking News & Updates on Corporate Responsibility Unit|Page 1

Visit Novartis Global Health on Twitter and Linkedin.
Friday, January 29, 2021 - 1:15am
CONTENT: Press Release
BASEL, SWITZERLAND,  January 29, 2021 /3BL Media/ A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to the end of 2025.
Widespread use of MDT has led to a 95% reduction in leprosy prevalence world-wide since its introduction the 1980s, though more than 200,000 cases are still seen every year.
1 Despite the huge impact of MDT, governments, donors, civil society and the private sector will need to collaborate on deploying additional tools if the world is to get to zero leprosy. ....

United States , Isabella Zinck , Samir Shah , Lutz Hegemann , Thomas Hungerbuehler , Sloan Simpson , Ren Minghui , Novartis Global Health Corporate Responsibility , Health Coverage Communicable , Global Health At Novartis , Lancet Global Health , World Health Organization , Novartis Global Health Corporate Responsibility Unit , Global Partnership For Zero Leprosy , Exchange Commission , Novartis Foundation , Chief Operating Officer , Global Health , Global Partnership , Zero Leprosy , Assistant Director General , Universal Health Coverage , Non Communicable Diseases , Novartis Global Health , Corporate Responsibility Unit , Corporate Responsibility ,